Home › Companies › Solid Biosciences Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Solid Biosciences Inc.’s Form 8-K, filed 2026-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2024-2025 2025-2026
Explore Solid Biosciences Inc. in the interactive database Compare manager voting policies
These tallies are Solid Biosciences Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Clare Kahn | 73,139,200 | -- | -- | 5,700,169 | 7,685,551 | Majority: yes |
| Elect Director: Adam Stone | 71,556,735 | -- | -- | 7,282,634 | 7,685,551 | Majority: yes |
| Elect Director: Lynne Sullivan | 73,124,331 | -- | -- | 5,715,038 | 7,685,551 | Majority: yes |
| Proposal 2: The Company's stockholders ratified the appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders. | 78,636,398 | 185,585 | 17,386 | -- | 7,685,551 | Majority: yes |
| Proposal 3: The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 86,420,186 | 70,007 | 34,727 | -- | -- | Majority: yes |
| Proposal 4: The Company's stockholders approved an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,000,000 (the "Share Increase Amendment"). | 85,604,508 | 893,360 | 27,502 | -- | -- | Majority: yes |
| The Company filed a Certificate of Amendment to Certificate of Incorporation with the Secretary of State of the State of Delaware on June 10, 2026 to effect the Share Increase Amendment. 5. | 72,596,980 | 6,203,634 | 38,755 | -- | 7,685,551 | Majority: yes |
Source: Solid Biosciences Inc., Form 8-K, filed with the SEC on 2026-06-10 — read the filing on EDGAR.
Each item below shows how the 149 asset managers that disclosed a Solid Biosciences Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Solid Biosciences Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
92% fund support · no official result
The 146 asset managers below cast 92% of the shares they voted on this item FOR (64,793,600 for, 5,942,379 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 11,055,900 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 9,339,978 | 0 | 0 | 0 | For |
| Fidelity | 8,569,794 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 7,690,405 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 3,565,062 | 0 | 0 | 0 | For |
| Vanguard | 3,347,939 | 4,789 | 0 | 0 | For |
| BlackRock | 3,325,397 | 11,607 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,649,449 | 22,467 | 0 | 0 | For |
| Vestal Point Capital, LP | 0 | 2,505,604 | 0 | 0 | Against |
| Redmile Group, LLC | 1,948,695 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 1,652,985 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| Citadel | 1,386,584 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,304,495 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 582,400 | 537,600 | 0 | 0 | For |
| State Street | 893,671 | 7,056 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 550,935 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 535,377 | 0 | 0 | Against |
| Woodline Partners LP | 479,795 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 478,889 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 0 | 441,200 | 0 | 0 | Against |
| Nuveen | 400,292 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Ally Bridge Group (NY) LLC | 358,257 | 0 | 0 | 0 | For |
Showing the 25 largest of 146 asset managers. See all 146 in the interactive database.
Combines 3 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Solid Biosciences Inc.’s own tally for this item (“Elect Director: Adam Stone”): 71,556,735 for, 7,282,634 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,449,606 outstanding shares: 73% for, 7% withheld (80% of the company cast a for/withheld vote).
The 44 asset managers below cast 100% of the shares they voted on this item FOR (13,357,348 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,980,065 | 0 | 5,429 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,487,648 | 0 | 44,895 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 97,235 | 0 | 52,080 | 0 | For |
| American Century | 0 | 0 | 114,392 | 0 | Abstain |
| Dimensional | 0 | 0 | 97,394 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 20,678 | 0 | 64,078 | 0 | Abstain |
| Northern Trust | 0 | 0 | 29,404 | 0 | Abstain |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 23,575 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 22,095 | 0 | Abstain |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 16,998 | 0 | 2,409 | 0 | For |
| State Street | 0 | 0 | 19,329 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 15,000 | 0 | Abstain |
| Brighthouse | 0 | 0 | 14,782 | 0 | Abstain |
| Jackson National | 0 | 0 | 13,761 | 0 | Abstain |
Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Solid Biosciences Inc.’s own tally for this item (“Elect Director: Clare Kahn”): 73,139,200 for, 5,700,169 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,449,606 outstanding shares: 74% for, 6% withheld (80% of the company cast a for/withheld vote).
The 44 asset managers below cast 100% of the shares they voted on this item FOR (13,540,791 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,981,826 | 0 | 3,668 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 97,235 | 0 | 52,080 | 0 | For |
| American Century | 0 | 0 | 114,392 | 0 | Abstain |
| Dimensional | 0 | 0 | 97,394 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,278 | 0 | 27,478 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 15,000 | 0 | Abstain |
| Brighthouse | 0 | 0 | 14,782 | 0 | Abstain |
| Jackson National | 0 | 0 | 13,761 | 0 | Abstain |
Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Solid Biosciences Inc.’s own tally for this item (“Elect Director: Lynne Sullivan”): 73,124,331 for, 5,715,038 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,449,606 outstanding shares: 74% for, 6% withheld (80% of the company cast a for/withheld vote).
The 44 asset managers below cast 100% of the shares they voted on this item FOR (13,539,031 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,980,066 | 0 | 5,428 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 97,235 | 0 | 52,080 | 0 | For |
| American Century | 0 | 0 | 114,392 | 0 | Abstain |
| Dimensional | 0 | 0 | 97,394 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,278 | 0 | 27,478 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 15,000 | 0 | Abstain |
| Brighthouse | 0 | 0 | 14,782 | 0 | Abstain |
| Jackson National | 0 | 0 | 13,761 | 0 | Abstain |
Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.
99% Majority: yes · of votes cast
Solid Biosciences Inc.’s own tally for this item (“Proposal 4: The Company's stockholders approved an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,00”): 85,604,508 for, 893,360 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,449,606 outstanding shares: 87% for, 1.0% against (88% of the company cast a for/against vote).
The 44 asset managers below cast 99.9% of the shares they voted on this item FOR (13,947,113 for, 1 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,985,493 | 1 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 149,315 | 0 | 0 | 0 | For |
| American Century | 114,392 | 0 | 0 | 0 | For |
| Dimensional | 97,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,756 | 0 | 0 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,000 | 0 | 0 | 0 | For |
| Brighthouse | 14,782 | 0 | 0 | 0 | For |
| Jackson National | 13,761 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Solid Biosciences Inc.’s own tally for this item (“Proposal 2: The Company's stockholders ratified the appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders.”): 78,636,398 for, 185,585 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,449,606 outstanding shares: 80% for, 0.2% against (80% of the company cast a for/against vote).
The 44 asset managers below cast 99.9% of the shares they voted on this item FOR (13,943,452 for, 3,662 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,981,832 | 3,662 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 149,315 | 0 | 0 | 0 | For |
| American Century | 114,392 | 0 | 0 | 0 | For |
| Dimensional | 97,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,756 | 0 | 0 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,000 | 0 | 0 | 0 | For |
| Brighthouse | 14,782 | 0 | 0 | 0 | For |
| Jackson National | 13,761 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.
99.9% Majority: yes · of votes cast
Solid Biosciences Inc.’s own tally for this item (“Proposal 3: The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 86,420,186 for, 70,007 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,449,606 outstanding shares: 88% for, 0.1% against (88% of the company cast a for/against vote).
The 44 asset managers below cast 100% of the shares they voted on this item FOR (13,947,114 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,839,219 | 0 | 0 | 0 | For |
| Vanguard | 2,985,494 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,595,479 | 0 | 0 | 0 | For |
| BlackRock | 1,532,543 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,253,978 | 0 | 0 | 0 | For |
| TIAA | 387,214 | 0 | 0 | 0 | For |
| Invesco | 231,907 | 0 | 0 | 0 | For |
| Charles Schwab | 160,725 | 0 | 0 | 0 | For |
| Equitable | 149,315 | 0 | 0 | 0 | For |
| American Century | 114,392 | 0 | 0 | 0 | For |
| Dimensional | 97,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,015 | 0 | 0 | 0 | For |
| JPMorgan | 94,041 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,756 | 0 | 0 | 0 | For |
| Northern Trust | 29,404 | 0 | 0 | 0 | For |
| Global X | 28,094 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 27,766 | 0 | 0 | 0 | For |
| Voya | 23,575 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,095 | 0 | 0 | 0 | For |
| Pacific Life | 21,916 | 0 | 0 | 0 | For |
| Nationwide | 19,407 | 0 | 0 | 0 | For |
| State Street | 19,329 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 15,000 | 0 | 0 | 0 | For |
| Brighthouse | 14,782 | 0 | 0 | 0 | For |
| Jackson National | 13,761 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.
Ranked by the number of Solid Biosciences Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 98,449,606 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 11.23% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.49% |
| 3 | Fidelity | 8.70% |
| 4 | Siren, L.L.C. | 7.81% |
| 5 | Deep Track Capital, LP | 3.62% |
| 6 | Vanguard | 3.41% |
| 7 | BlackRock | 3.39% |
| 8 | FRANKLIN ADVISERS INC | 2.71% |
| 9 | Vestal Point Capital, LP | 2.55% |
| 10 | Redmile Group, LLC | 1.98% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 12.23% | 13D |
| Perceptive Life Sciences Master Fund, Ltd. and affiliated entities | 12.16% | DEF14A |
| Entities affiliated with Bain Capital Life Sciences Investors, LLC | 10.58% | DEF14A |
| Invus Public Equities, L.P. and affiliated entities | 10.23% | DEF14A |
| Raymond Debbane | 10.23% | 13G |
| Entities affiliated with RA Capital Management, L.P. | 10.08% | DEF14A |
| Entities associated with Vestal Point Capital, LP | 9.61% | DEF14A |
| BCLS II Investco, LP | 8.74% | 13D |
| BlackRock | 5.04% | 13F |
| Vestal Point Capital, LP | 4.91% | 13G |
Percentages above are of 98,449,606 shares outstanding, as reported by Solid Biosciences Inc. on its Form 10-Q dated 2026-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Solid Biosciences Inc.’s 10-Q dated 2026-05-08. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Solid Biosciences Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 149 asset managers reported how they voted in their SEC Form N-PX filings, covering 959 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Solid Biosciences Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — THE APPROVAL OF AN ADVISORY VOTE ON EXECUTIVE COMPENSATION. — the reporting funds cast 92% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.
Solid Biosciences Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).